The Cali Fund's Stark Reality: Big Pharma's $7,085 Commitment to a $1 Billion Vision

The global biodiversity finance landscape has, for years, grappled with a monumental funding gap. Against this backdrop, the Cali Fund emerged with an ambitious target: to funnel $1 billion annually from pharmaceutical companies into nature conservation, particularly in low-income countries. More than 18 months post-launch, the reality is starkly different.

As the Cop17 biodiversity summit commenced in Yerevan, Armenia, the Cali Fund's ledger revealed just $10,656 in total commitments, with a meager $7,085 actually deposited. This represents a minuscule fraction of its annual goal, triggering accusations of “free-riding on nature” against major pharmaceutical players whose business models are inherently linked to genetic information derived from the natural world.

Zero Carbon Analytics (ZCA) research underscores the scale of the disparity. The top 15 pharmaceutical companies generated an estimated $161 billion in profits in 2025. Had these companies adhered to the Cali Fund’s voluntary guideline of contributing 1% of profits or 0.1% of revenue, the fund could have seen contributions of around $756 million. The current $7,085 commitment stands in sharp contrast to these potential figures, prompting June Rubis of Macquarie University, an Indigenous peoples’ representative on the Cali Fund’s steering committee, to declare, “Definitely, they’re free-riding.”

**Profits vs. Preservation: An Unbalanced Ledger**

The economic implications of this shortfall are profound. The pharmaceutical industry's reliance on genetic information for lucrative new medicines positions it as a direct beneficiary of biodiversity. Yet, its financial contribution to the preservation of this foundational resource remains virtually non-existent. The argument from advocates like Rubis is clear: businesses are failing to recognize the vital link between protecting nature and safeguarding their future profits, let alone supporting the frontline communities defending biodiversity.

Further analysis by ZCA reveals that the total sum distributed to shareholders by the top 15 pharmaceutical companies in 2025 was 175 times greater than their suggested contribution to the Cali Fund. This disparity signals a prioritization of short-term shareholder returns over long-term ecological and, by extension, corporate sustainability. Victoria Kalyvas, author of the ZCA analysis, articulates the gravity of the situation: “The future of health is written in nature’s DNA… The pharmaceutical industry stands to lose a great deal from its destruction, as do patients.”

**The Digital Dilemma: Valuing Nature's Genetic Code**

One layer of complexity in securing these contributions stems from advancements in biotechnology. The proliferation of digital sequence information (DSI) stored in public databases has made it increasingly challenging to track and attribute the commercial use of genetic resources to specific natural origins. This technological evolution, while enabling scientific progress, inadvertently complicates the establishment of equitable benefit-sharing mechanisms, leaving the door open for industries to leverage nature’s bounty without commensurate recompense.

**Implications for Global Conservation Funding**

The Cali Fund's predicament casts a long shadow over wider efforts to plug a staggering $700 billion global funding gap for nature conservation. The failure to mobilize capital from an industry that directly profits from biodiversity highlights a systemic issue in how natural capital is valued—or, more accurately, undervalued—in global economic frameworks. With at least half of the Cali Fund's money earmarked for priorities identified by Indigenous peoples and local communities, its undercapitalization also represents a missed opportunity for empowering those most directly involved in biodiversity stewardship.

The minimal uptake of the Cali Fund serves as a critical test case for corporate accountability and the willingness of industries to internalize the environmental costs of their operations. The ongoing Cop17 discussions face the challenge of transforming rhetorical commitments into tangible financial flows, ensuring that the critical genetic information underpinning future health is not exploited without contributing to its very source.